An Overview Of Viral Pandemics Over The Past Decade
Özet
Viral epidemics have been a persistent global challenge, posing significant threats to public health, economies, and societies. In the past decade, several major outbreaks have emerged, including the Zika virus (2015–2016), the Ebola outbreak in the Democratic Republic of Congo (2018–2020), the COVID-19 pandemic (2019–present), and the Monkeypox outbreak (2022). Each of these epidemics has demonstrated the rapid transmission of infectious diseases and their severe consequences, emphasizing the importance of preparedness and effective public health responses. The COVID-19 pandemic, in particular, has exposed vulnerabilities in global healthcare systems and highlighted the need for robust surveillance, vaccine development, and coordinated international efforts. While advancements in medical science have improved the response to such outbreaks, factors like urbanization, climate change, and increased human-animal interactions continue to contribute to the emergence of new viral threats. This review aims to provide a comprehensive analysis of recent viral epidemics by examining their origins, global spread, health impacts, and response strategies. By studying past outbreaks, we seek to identify key lessons and challenges that can improve epidemic preparedness. Furthermore, this article discusses whether the world is adequately prepared for future epidemics and explores strategies to enhance global readiness. Strengthening early warning systems, ensuring equitable access to vaccines, and improving international collaboration will be crucial in mitigating future pandemics. Understanding past epidemics can serve as a guide to prevent, control, and manage future viral threats more effectively.
Referanslar
Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus–The species and its viruses, a statement of the Coronavirus Study Group. BioRxiv. 2020.
National Health Commission's briefing on the pneumonia epidemic situation. Released on 23 Feb 2020.
Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. Journal of medical virology. 2020.
Wu F ZS, Bin Y, Chen YM, Wang W, Song ZG, Hu Y, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020.
Zhou P YX, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020.
Ji W, Wang W, Zhao X, Zai J, Li X. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross‐species transmission from snake to human. Journal of medical virology. 2020.
Benvenuto D, Giovannetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-new coronavirus epidemic: evidence for virus evolution. J Med Virol 2020.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223):497-506.
Wu P, Hao X, Lau EH, Wong JY, Leung KS, Wu JT, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Eurosurveillance. 2020;25(3).
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020.
Xu Z, Peng C, Shi Y, Zhu Z, Mu K, Wang X, et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv. 2020.
Wang C HP, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020.
Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv. 2020.
Mirza, A. Z., Shamshad, H., Osra, F. A., Habeebullah, T. M., & Morad, M. (2021). An overview of viruses discovered over the last decades and drug development for the current pandemic. European Journal of Pharmacology, 890, 173746.
Maclachlan, N. J., & Dubovi, E. J. (Eds.). (2010). Fenner's veterinary virology. Academic press.
Xu Z, Peng C, Shi Y, Zhu Z, Mu K, Wang X, et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv. 2020
Tai DY. Pharmacologic treatment of SARS: current knowledge and recommendations. AnnalsAcademy of Medicine Singapore. 2007;36(6):438.
Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-6.
Chong YP, Song JY, Seo YB, Choi JP, Shin HS, Team RR. Antiviral treatment guidelines for Middle East respiratory syndrome. Infection & chemotherapy. 2015;47(3):212-22.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020:1-3.
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). BioScience Trends. 2020.
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. New England Journal of Medicine. 2020.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020.
Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes and Infection. 2020.
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). BioScience Trends. 2020.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020.
Singh, A. K., Singh, A., Shaikh, A., Singh, R., & Misra, A. (2020). Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
Chen, C., Huang, J., Cheng, Z., Wu, J., Chen, S., Zhang, Y., ... & Yin, P. (2020). Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv.
